CTC microfluidic chip test to solve cancer treatment issues
There are two common dilemmas in the treatment of cancer today: the first is that many therapies, including chemotherapies and radiation can debilitate healthy cells, to the point of killing the person before defeating the cancer.
The second problem is that many cancer cells, responding to a prevention drug, can quickly mutate to become immune and more resilient. Recent advances in circulating tumor cell technology (CTC) however, headed by Dr. Daniel Haber, Director at Massachusetts General Hospital Cancer Center and Dr. Mehmet Toner, Director of the Center for BioMicroElectroMechanical Systems, address this mutation problem head on. Their research has also found support from The American Association of Cancer Research, the American Cancer Society and The Jeffrey Epstein VI Foundation, which supports cutting edge medical research around the world.